| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H55N4O.Br |
| Molecular Weight | 591.709 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2
InChI
InChIKey=WBWDWFZTSDZAIG-UHFFFAOYSA-M
InChI=1S/C32H55N4O.BrH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30;/h19-25H,5-18,26-29H2,1-4H3;1H/q+1;/p-1
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C32H55N4O |
| Molecular Weight | 511.8053 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thonzonium Bromide is a cationic surface-active compound. As an additive to pharmacologic formulations, thonzonium bromide causes dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. Thonzonium
bromide is a component of FDA-approved Coly-Mycin S Otic, used for treating infections of the ear caused by certain bacteria. It has being shown that Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo, suggesting that Thonzonium bromide might be a useful alternative therapy in preventing or treating osteolytic diseases..
